GlassScriptPhysician profile
Laurence I Radin
NPI 1508860156
$14,813.77
in general payments reported to CMS, 2019-2025
67 companies · $654 in 2025
The $654 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,147 · 2020: $2,548 · 2021: $2,962 · 2022: $2,826 · 2023: $2,312 · 2024: $364 · 2025: $654.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,260 · Education: $70.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,259.93 |
| Education | $70.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,098.90 | 2019-2025 | |
| Biogen, INC. | $1,071.74 | 2019-2025 | Tysabri, Vumerity, Tysabri |
| Emd Serono, INC. | $1,019.53 | 2019-2023 | Mavenclad |
| Abbvie INC. | $1,008.11 | 2021-2025 | |
| Amgen INC. | $702.95 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $678.37 | 2019-2023 | Ongentys, Ingrezza |
| Ucb, INC. | $661.06 | 2019-2025 | Briviact, Rystiggo, Fintepla |
| Teva Pharmaceuticals USA, INC. | $629.36 | 2019-2023 | Austedo, Austedo Xr |
| Sunovion Pharmaceuticals INC. | $573.18 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $542.86 | 2019-2022 | |
| Genzyme Corporation | $521.01 | 2019-2021 | |
| Eisai INC. | $511.93 | 2019-2025 | |
| Lundbeck LLC | $450.61 | 2019-2023 | Vyepti |
| Sk Life Science, INC. | $432.73 | 2020-2023 | Xcopri |
| Pfizer INC. | $367.56 | 2019-2025 |
Show all 65 companies
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laurence Radin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.